Insider Selling: Moderna, Inc. (NASDAQ:MRNA) CEO Sells 40,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $133.89, for a total value of $5,355,600.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $724,605,449.94. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Stephane Bancel also recently made the following trade(s):

  • On Thursday, May 19th, Stephane Bancel sold 10,000 shares of Moderna stock. The shares were sold at an average price of $140.96, for a total value of $1,409,600.00.
  • On Wednesday, May 11th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $127.13, for a total value of $1,144,170.00.
  • On Wednesday, April 27th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $142.14, for a total value of $1,279,260.00.
  • On Wednesday, April 20th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $150.59, for a total value of $1,355,310.00.
  • On Wednesday, April 13th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $170.26, for a total value of $1,532,340.00.
  • On Wednesday, April 6th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $158.70, for a total value of $1,428,300.00.
  • On Wednesday, March 30th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $176.83, for a total value of $1,591,470.00.
  • On Wednesday, March 23rd, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $180.15, for a total value of $1,621,350.00.
  • On Wednesday, March 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $161.63, for a total value of $1,454,670.00.

Shares of NASDAQ:MRNA traded up $11.86 during midday trading on Friday, reaching $147.66. The company’s stock had a trading volume of 7,538,648 shares, compared to its average volume of 7,593,198. The firm has a market cap of $58.73 billion, a price-to-earnings ratio of 4.33, a price-to-earnings-growth ratio of 0.81 and a beta of 1.70. The company has a quick ratio of 1.56, a current ratio of 1.77 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 1 year low of $119.01 and a 1 year high of $497.49. The business has a 50 day moving average price of $152.84 and a 200 day moving average price of $190.11.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $8.58 EPS for the quarter, beating analysts’ consensus estimates of $5.18 by $3.40. The business had revenue of $6.07 billion during the quarter, compared to the consensus estimate of $4.43 billion. Moderna had a return on equity of 121.86% and a net margin of 64.77%. The business’s revenue for the quarter was up 213.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 earnings per share. Sell-side analysts anticipate that Moderna, Inc. will post 27.22 earnings per share for the current fiscal year.

Several brokerages recently issued reports on MRNA. Deutsche Bank Aktiengesellschaft reduced their price objective on Moderna from $175.00 to $155.00 and set a “hold” rating for the company in a report on Monday, March 7th. Jefferies Financial Group reduced their price objective on Moderna from $200.00 to $170.00 in a report on Friday, February 25th. Redburn Partners raised Moderna from a “sell” rating to a “neutral” rating in a research report on Tuesday, February 1st. Barclays dropped their price target on Moderna from $404.00 to $210.00 in a research report on Friday, February 25th. Finally, TheStreet downgraded Moderna from a “b-” rating to a “c+” rating in a research report on Thursday, February 24th. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $236.62.

A number of hedge funds have recently bought and sold shares of the business. Ninety One UK Ltd grew its position in Moderna by 67.8% during the first quarter. Ninety One UK Ltd now owns 57,757 shares of the company’s stock valued at $9,949,000 after acquiring an additional 23,344 shares during the period. L.M. Kohn & Company purchased a new stake in Moderna during the first quarter valued at about $315,000. M Holdings Securities Inc. purchased a new stake in Moderna during the first quarter valued at about $430,000. Advisory Services Network LLC grew its position in Moderna by 27.4% during the first quarter. Advisory Services Network LLC now owns 4,602 shares of the company’s stock valued at $793,000 after acquiring an additional 990 shares during the period. Finally, Aurora Investment Counsel lifted its stake in shares of Moderna by 21.0% during the first quarter. Aurora Investment Counsel now owns 7,031 shares of the company’s stock worth $1,211,000 after purchasing an additional 1,221 shares in the last quarter. 61.20% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

Featured Stories

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.